Ipamorelin dosage

Protocol

1. 1

   Reconstitute the vial

   A typical 5 mg vial reconstituted with 2 mL bacteriostatic water gives 2.5 mg/mL (2500 mcg/mL). A 200 mcg dose equals 8 units on a U100 insulin syringe.

   Open tool →
2. 2

   Measure the dose

   Typical Ipamorelin dose is 0.2 mg (200 to 300 mcg per injection, 2 to 3 times daily. Pre-bed dose produces the most consistent subjective effect.). Use a weight-based calculator for individual adjustments.

   Open tool →
3. 3

   Set the frequency

   Administer 2-3x daily. Half-life of 2 hours anchors the dosing interval.

   Open tool →
4. 4

   Cycle if needed

   Anecdotal protocols run 8 to 12 weeks on, then 4 weeks off. No published controlled cycling data.

   Open tool →
5. 5

   Monitor for side effects

   Watch for: injection-site irritation; vivid dreams; transient mild head pressure; occasional headache. Stop or reduce dose if tolerability breaks down.

Why this dose

Selective GHS-R1a agonist that stimulates pulsatile GH release with minimal cortisol or prolactin co-activation. Suppresses hypothalamic somatostatin and stimulates pituitary somatotrophs.

The typical dose (0.2 mg) reflects 200 to 300 mcg per injection, 2 to 3 times daily. Pre-bed dose produces the most consistent subjective effect.. Individual response varies with body weight, baseline status, concurrent training, and concurrent medications, so the labeled range is the starting point rather than the prescription.

How to administer

Ipamorelin is administered via the subcutaneous or intravenous routes. Subcutaneous injection into rotated abdominal sites is the standard self-administration approach for peptide protocols; rotate sites to limit local irritation. Use a fresh insulin syringe per dose.

Onset of action runs around 15 minutes after administration. Peak effect lands near 1 hour post-dose. Plan the administration window so that peak effect lines up with whatever outcome you are dosing for, whether that is training, sleep, or symptom coverage.

Half-life note: ~2 hour plasma half-life is the longest among synthetic GHRPs, supporting once-daily or multi-daily dosing without rapid clearance.

Cycling and tolerance

Anecdotal protocols run 8 to 12 weeks on, then 4 weeks off. No published controlled cycling data.

The cycling rationale for receptor-active compounds is partly empirical and partly mechanistic: continuous high-dose stimulation can downregulate target receptors or accelerate negative-feedback loops on endogenous production. Built-in off-periods give the system time to resensitize before the next phase, which preserves the effective dose-response over a longer arc.

Effects to expect at typical dose

• Pentapeptide GHS-R1a agonist with the cleanest selectivity profile in the GHRP class
• Minimal cortisol and prolactin elevation at standard doses (substantially less than GHRP-2 or hexarelin)
• ~2 hour plasma half-life, longest of the synthetic GHRPs
• Largest human safety database (~600 participants in Helsinn's postoperative ileus phase 2)
• Standard pairing for CJC-1295 no-DAC at 200 to 300 mcg subcutaneously 2 to 3 times daily
• Banned by WADA under S2; never reached registration despite phase 2b development

Side effects and interactions

Common side effects

• injection-site irritation
• vivid dreams
• transient mild head pressure
• occasional headache

Notable interactions

• insulin (moderate): sustained GH can blunt insulin sensitivity over weeks
• corticosteroids (moderate): blunt GH response; reduce expected efficacy
• CJC-1295 (minor): synergistic GH release via parallel GHRH and ghrelin pathways; standard pairing
• sermorelin (minor): additive GH release; functionally similar pairing to CJC-1295 with shorter GHRH half-life

Lists above cover commonly reported and well-characterized items. They are not exhaustive: review the full Ipamorelin profile and discuss with a clinician familiar with your medication list before starting, particularly if you are on prescription therapy or have a chronic condition.

Regulatory snapshot

WADA status

banned

DEA / Rx

Not scheduled (research chemical)

Pregnancy

Insufficient data; not recommended

Legal status

Not FDA approved; advanced through phase 2b in postoperative ileus before discontinuation; research-use-only grey market; banned by WADA

Do not use if

• pregnancy
• active malignancy
• history of pituitary tumor
• uncontrolled diabetes

Related research